Δ40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs

  1. Heidi Scrable1,3
  1. 1Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota 55905, USA;
  2. 2Graduate Program in Molecular Cell and Developmental Biology, University of Virginia, Charlottesville, Virginia 22908, USA

    Abstract

    Δ40p53 is a transactivation-deficient isoform of the tumor suppressor p53. We discovered that Δ40p53, in addition to being highly expressed in embryonic stem cells (ESCs), is the major p53 isoform during early stages of embryogenesis in the mouse. By altering the dose of Δ40p53 in ESCs, we identified a critical role for this isoform in maintaining the ESC state. Haploinsufficiency for Δ40p53 causes a loss of pluripotency in ESCs and acquisition of a somatic cell cycle, while increased dosage of Δ40p53 prolongs pluripotency and inhibits progression to a more differentiated state. Δ40p53 controls the switch from pluripotent ESCs to differentiated somatic cells by controlling the activity of full-length p53 at critical targets such as Nanog and the IGF-1 receptor (IGF-1R). The IGF axis plays a central role in the switch between pluripotency and differentiation in ESCs—and Δ40p53, by controlling the level of the IGF-1R, acts as a master regulator of this switch. We propose that this is the primary function of Δ40p53 in cells of the early embryo and stem cells, which are the only normal cells in which this isoform is expressed.

    Keywords

    Footnotes

    • Received April 27, 2010.
    • Accepted September 14, 2010.
    | Table of Contents

    Life Science Alliance